

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01017/36263

Serial No.

TBD

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Liu et al.

Filing Date

Herewith

Group

TBD



 JCB78 U.S. PTO
 09/428838
 10/22/99


U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
A	A1	3,691,016	09/12/72				
A	A2	3,941,763	03/02/76				
A	A3	3,969,287	07/13/76				
A	A4	4,195,128	03/25/80				
A	A5	4,247,642	01/27/81				
A	A6	4,229,537	10/21/80				
A	A7	4,289,872	09/15/81				
A	A8	4,330,440	05/18/82				
A	A9	4,925,673	05/15/90				
A	A10	5,013,556	05/07/91				
A	A11	5,229,490	07/20/93				
A	A12	5,284,656	02/08/94				
A	A13	5,428,130	06/27/95				
A	A14	5,480,981	01/02/96				
A	A15	5,739,277	04/14/98				
A	A16	5,792,451	08/11/98				
A	A17	5,869,451	02/09/99				
A	A18	5,932,546	08/03/99				

EXAMINER



DATE CONSIDERED



*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. 01017/36263	Serial No. TBD
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		Applicant Liu et al.	
		Filing Date Herewith	Group TBD

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
A	B1	WO 93/21259	10/28/93	PCT				
A	B2	WO 95/18858	07/13/95	PCT				
A	B3	WO 95/21919	08/17/95	PCT				
A	B4	WO 95/21920	08/17/95	PCT				
A	B5	WO 95/26746	10/12/95	PCT				
A	B6	WO 96/32478	10/17/96	PCT				
A	B7	WO 96/40189	12/19/96	PCT				
A	B8	WO 96/40750	12/19/96	PCT				
A	B9	WO 97/34631	09/25/97	PCT				
A	B10	WO 98/25965	06/18/98	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C1	Abuchowski and Davis, Soluble Polymer-Enzyme Adducts, Enzymes as Drugs, Hoenberg and Roberts, eds., Wiley-Interscience, New York, NY, (1981), pp 367-383
C2	Adjei et al., Pharmaceutical Research 7:565-569 (1990)
C3	Adjei et al., International Journal of Pharmaceutics 61:135-144 (1990)
C4	Alexander et al., Blood 87:2162-2170 (1996)
C5	Bartley et al., Cell 77:1117-1124 (1994)
C6	Basser et al., Lancet 348:1279-81 (1996)

EXAMINER 	DATE CONSIDERED 12/27/01
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01017/36263

Serial No.

TBD

INFORMATION DISCLOSURE STATEMENT

Applicant

Liu et al.

Filing Date

Herewith

Group

TBD

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C7	Braquet et al., Journal of Cardiovascular Pharmacology 13 (suppl.5): s. 143-146 (1989)
C8	Capon, et al., Nature 337:525-531 (1989)
C9	Chang et al., Journal of Biological Chemistry 270:511-517 (1995)
C10	Choi et al., Blood 85:402-413 (1995)
C11	Clackson, T. et al., Science 267:383-386 (1995)
C12	Creighton, T.E., Proteins: Structure and Molecule Properties, W.H. Freeman & Co., San Francisco, pp. 70-86 (1983)
C13	Cwirla, S.E. et al., Science 276:1696-1699 (1997)
C14	Davis et al., Biochem. Intl. 10:395-404 (1985)
C15	Debili, N. et al., Blood 85:391-401 (1995)
C16	Debs et al., The Journal of Immunology 140:3482-3488 (1988)
C17	de Sauvage et al., Nature 369:533-538 (1994)
C18	Devlin, J.J. et al., Science 249:404 (1990)
C19	Duncan, Nature, 332:563 (1988)
C20	Ellison, J.W. et al., Nucleic Acids Res. 10:4071-4079 (1982)
C21	Erickson et al., The Proteins, 3rd ed., vol. 2, pp. 257-527 (1976)
C22	Finn et al., The Proteins, 3rd ed., vol. 2, pp. 105-253 (1976)
C23	Fisher, C. et al., N. Engl. J. Med., 334:1697-1702 (1996)
C24	Gurney et al., Blood 85:981-988 (1995)
C25	Harvill et al., Immunotechnology, 1:95-105 (1995)
C26	Hokom, M.M. et al., Blood 86:4486-4492 (1995)
C27	Hubbard et al., Annals of Internal Medicine 111:206-212 (1989)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01017/36263

Serial No.

TBD

INFORMATION DISCLOSURE STATEMENT

Applicant

Liu et al.

Filing Date

Herewith

Group

TBD

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

C28	Jefferis et al., Immunology Letters, Vol. 44, pp. 111-117 (1995)
C29	Jefferis et al., Molecular Immunology, Vol. 27, pp. 1237-1240 (1990)
C30	Johnson et al., Biochemistry, Vol. 37, pp. 3699-3710 (1998)
C31	Kaushansky et al., Nature 369:568-571 (1994)
C32	Kato et al., Journal of biochemistry 118:229-236 (1995)
C33	Kay et al., Reviews - Research Focus, Vol. 3, No. 8, pp. 370-378 (1998)
C34	Kuter et al., Proc. Natl. Acad. Sci. USA 91:11104-11108 (1994)
C35	Livnah, O. et al., Science 273:464-471 (1996)
C36	Lok, S. et al., Nature 369:565-8 (1994)
C37	Marshall, K., Modern Pharmaceuticals, Edited by G. S. Banker and C. T. Rhodes Chapter 10, 1979
C38	Merrifield, in Chem. Polypeptides, pp. 335-61 (Katsoyannis and Panayotis eds. 1973)
C39	Merrifield, J. Am. Chem. Soc. 85:2149 (1963)
C40	Methia et al., Blood 82:1395-1401 (1993)
C41	Newmark, et al., J. Appl. Biochem. 4:185-189 (1982)
C42	Palacios, R. et al., Cell 41:727 (1985)
C43	Rasko et al., Stem Cells 15:33-42 (1997)
C44	Ravin et al., Remington's Pharmaceutical Sciences, 18th Ed. (1990, Mack Publishing Co., Easton, PA 18042) pages 1435-1712
C45	Sarmay, Molecular Immunology, Vol. 29, No. 5, 633-639 (1992)
C46	Scott, J.K. et al., Science 249:386 (1990)
C47	Sheridan et al., Platelets, Vol. 8, pp. 319-332 (1997)


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	Atty. Docket No. 01017/36263	Serial No. TBD
	Applicant Liu et al.	
	Filing Date Herewith	Group TBD

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
C48	Smith et al., J. Clin. Invest. 84:1145-1146 (1989)	
C49	Stewart and Young, Solid Phase Peptide Synthesis (1969) Table of Contents only	
C50	Syed et al., Nature, 395:5111 (1998)	
C51	Ulich et al., Blood 86:971-976 (1995)	
C52	Van Zee, K. et al., The Journal of Immunology, 156:2221-2230 (1996)	
C53	Vigon, I. et al., Proc. Natl. Acad. Sci. USA 89:5640-5644 (1992)	
C54	Wells, J. A. et al., Ann. Rev. Biochem. 65:609-634 (1996)	
C55	Wrighton, N.C., et al., Science 273:458-469 (1996)	
C56	Wrighton, N.C., et al., Nature Biotechnology 15:1261-1265 (1997)	
C57	Zeigler et al., Blood 84:4045-4052 (1994)	
C58	Zheng, X. et al., The Journal of Immunology, 154:5590-5600 (1995)	

EXAMINER 	DATE CONSIDERED <u>12/22/91</u>
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	